- Home
- HSIC vs MDGL Comparison
HSIC vs MDGL Comparison
Compare HSIC & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSIC
- MDGL
- Stock Information
- Founded
- HSIC 1932
- MDGL 2011
- Country
- HSIC United States
- MDGL United States
- Employees
- HSIC N/A
- MDGL N/A
- Industry
- HSIC Medical Specialities
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- HSIC Health Care
- MDGL Health Care
- Exchange
- HSIC Nasdaq
- MDGL Nasdaq
- Market Cap
- HSIC 8.5B
- MDGL 9.6B
- IPO Year
- HSIC 1995
- MDGL N/A
- Fundamental
- Price
- HSIC $73.46
- MDGL $521.67
- Analyst Decision
- HSIC Buy
- MDGL Strong Buy
- Analyst Count
- HSIC 14
- MDGL 13
- Target Price
- HSIC $75.71
- MDGL $529.00
- AVG Volume (30 Days)
- HSIC 1.7M
- MDGL 410.1K
- Earning Date
- HSIC 11-04-2025
- MDGL 11-04-2025
- Dividend Yield
- HSIC N/A
- MDGL N/A
- EPS Growth
- HSIC 30.70
- MDGL N/A
- EPS
- HSIC 3.17
- MDGL N/A
- Revenue
- HSIC $12,938,000,000.00
- MDGL $740,640,000.00
- Revenue This Year
- HSIC $4.60
- MDGL $395.75
- Revenue Next Year
- HSIC $3.44
- MDGL $65.73
- P/E Ratio
- HSIC $22.99
- MDGL N/A
- Revenue Growth
- HSIC 3.51
- MDGL 864.21
- 52 Week Low
- HSIC $60.56
- MDGL $265.00
- 52 Week High
- HSIC $82.49
- MDGL $544.25
- Technical
- Relative Strength Index (RSI)
- HSIC 70.31
- MDGL 68.38
- Support Level
- HSIC $69.13
- MDGL $399.00
- Resistance Level
- HSIC $73.63
- MDGL $544.25
- Average True Range (ATR)
- HSIC 1.82
- MDGL 27.35
- MACD
- HSIC 0.99
- MDGL 9.88
- Stochastic Oscillator
- HSIC 97.91
- MDGL 82.58
About HSIC Henry Schein Inc.
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology. It generates the majority of its revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.